KP-2025

RMP114-mIgG1-D265A

47592

Home » RMP114-mIgG1-D265A

Background of RMP114-mIgG1-D265A

RMP114-mIgG1-D265A is a precision-engineered monoclonal antibody targeting murine PD-1, featuring a D265A mutation in the mIgG1 Fc region to enhance stability and minimize immunogenicity. This variant allows for specific PD-1 inhibition in preclinical models, minimizing off-target effects. Designed for research, RMP114-mIgG1-D265A offers high specificity and purity, suitable for a variety of applications including in vitro and in vivo studies. It serves as a versatile tool for unraveling PD-1 signaling in murine models, supporting the development of novel immunotherapies. In summary, RMP114-mIgG1-D265A provides researchers with a robust and low-immunogenicity alternative for studying PD-1 in immunology and oncology research.

Specifications

Catalog Number	KP-2025
Antibody Name	RMP114-mIgG1-D265A
Isotype	Mouse IgG1, kappa
FC Muations	D265A
Target	Mouse PD1
Species Reactivity	Mouse
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	20mM sodium citrate,150mM NaCl, pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA \| FACS\| in vivo animal study
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Ribas A. & Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.
Yamazaki T. et al.,2005. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol. 175(3):1586-92.
Brüggemann M. et al., 1989. The immunogenicity of chimeric antibodies. J. Exp. Med. 170:2153-2157.
Mall C. et al., 2016. Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology. 5(2):e1075114.